3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
2
Esophageal Neoplasms
2
Ovarian Neoplasms
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
Gemcitabine
22
Fluorouracil
14
Oxaliplatin
13
Capecitabine
13
Paclitaxel
12
pembrolizumab
11
Cisplatin
11
Carboplatin
11
Pemetrexed
10
Leucovorin
9
130-nm albumin-bound paclitaxel
9
Ramucirumab
8
zolbetuximab
7
Albumin-Bound Paclitaxel
7
trastuzumab deruxtecan
6
Drug Therapy
5
Docetaxel
5
Bevacizumab
5
Nivolumab
4
Irinotecan
4
vandetanib
3
cemiplimab
3
Everolimus
3
EC145
3
tislelizumab
2
technetium 99m etarfolatide
2
spartalizumab
2
pralsetinib
2
osimertinib
2
nimotuzumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Adenocarcinoma
×
matuzumab
×
Clear all
NCT00215644
2018-11-02
MATRIX EG
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
72 enrolled
7 charts